Trial intelligence / Profile preview

TOP1288 rectal solution in moderate to severe ulcerative colitis

2016-000390-20Phase 2Completed

Sponsor
TopiVert Pharma Limited
Start
Jun 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in autoimmune colitis comparing TOP1288 with Placebo (2 arms). Primary endpoint: Endoscopic remission after 4 weeks. Started Jun 2016; status: completed.

02

Drugs

TOP-1288
03

Conditions

autoimmune colitis

Beyond the preview

Go deeper on 2016-000390-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-000390-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call